Latest Updates of Key Players in the U.S. AI in Oncology Market with Key Developments
Company Updates
| Company | Headquarters | Latest Update |
| GE HealthCare | United States | GE HealthCare debuts AI-supported solution, designed to improve and shorten the radiation therapy workflow. |
| Siemens Healthineers AG | United States | In February 2025, Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. |
| NVIDIA Corporation | Florida | In January 2026, NVIDIA and Eli Lilly plan to invest up to $1B over five years in a joint AI lab to tighten the loop between model building and wet lab validation. |
| IBM | United States | Researchers are training AI to detect invisible immune activity within tumors using only standard pathology slides. |
| Tempus Labs, Inc. | United States | In February 2026, Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine, announced a partnership with Median Technologies to bring Median’s proprietary eyonis LCS to the Tempus Pixel platform. |
| ConcertAI | United States | In February 2026, ConcertAI launches Accelerated Clinical Trials (ACT), an agentic AI platform built on CARAai to accelerate clinical trials |
| PathAI, Inc | United States | PathAI and University Hospital Zurich Announce Collaboration to Deploy AISight Dx and AIM-TumorCellularity for Routine Molecular Pathology Workflows. |
Market Growth
The U.S. AI in oncology market size was estimated at USD 720.04 million in 2025 and is predicted to increase from USD 921.29 million in 2026 to approximately USD 8467.58 billion by 2035, expanding at a CAGR of 27.95% from 2026 to 2035.
Recent Developments in the U.S. AI in Oncology Market
- In February 2026, PathAI announced the strategic expansion of its support of inflammatory bowel disease clinical trials on the AISight Clinical Trials Platform with the launch of IBDExplore to join AIM-HI UC.
- In January 2026, 10x Genomics, Inc., a leader in single-cell and spatial biology, today announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through high-resolution molecular data and AI.
- In January 2026, the Mount Sinai Tisch Cancer Center (TCC) launched a novel artificial intelligence (AI) platform to help connect more cancer patients across the Mount Sinai Health System to life-saving clinical trials.
- In January 2026, Modella AI announced that it had been acquired by AstraZeneca, expanding the companies’ existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca’s global oncology portfolio.
Make smarter moves with all your Oncology insights and data under one roof - Access the Dashboard
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
